8-K: Checkpoint Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Checkpoint Therapeutics reported its Q3 2024 financial results, highlighted by a strengthened cash position and progress on its cosibelimab Biologics License Application (BLA).

Summary

• Checkpoint Therapeutics announced its financial results for the third quarter ended September 30, 2024, along with recent corporate updates.
• The company's Biologics License Application (BLA) for cosibelimab is under review by the U.S. FDA, with a PDUFA goal date of December 28, 2024.
• Checkpoint received $9.2 million in cash proceeds from the exercise of existing warrants in November 2024, improving its cash position.
• The company's cash and cash equivalents totaled $4.7 million as of September 30, 2024, a decrease of $0.3 million for the quarter.
• Research and development expenses for Q3 2024 were $6.4 million, an increase of $0.9 million compared to Q3 2023.
• General and administrative expenses for Q3 2024 were $3.4 million, an increase of $1.2 million compared to Q3 2023.
• The net loss attributable to common stockholders for Q3 2024 was $9.7 million, or $0.23 per share, compared to a net loss of $5.7 million, or $0.29 per share, in Q3 2023.
• Checkpoint completed a registered direct offering and private placement in July 2024, raising approximately $12.0 million in gross proceeds.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there is progress on the BLA and a strengthened cash position, the increased net loss and expenses are concerning. The company is still reliant on regulatory approval and future funding.

Positives

• The company's cash position was strengthened by $9.2 million in November 2024 through warrant exercises.
• The BLA for cosibelimab is under review by the FDA with a PDUFA goal date set for December 28, 2024.
• Longer-term data for cosibelimab showed improved response rates over time.
• Checkpoint secured $12.0 million in gross proceeds through a direct offering and private placement in July 2024.
• The company is preparing for the potential approval of cosibelimab.

Negatives

• The company's cash and cash equivalents decreased by $0.3 million in Q3 2024.
• The net loss increased to $9.7 million in Q3 2024 from $5.7 million in Q3 2023.
• Research and development expenses increased by $0.9 million in Q3 2024 compared to Q3 2023.
• General and administrative expenses increased by $1.2 million in Q3 2024 compared to Q3 2023.

Risks

• The FDA may not approve the BLA for cosibelimab.
• There are risks associated with the regulatory review process and timelines.
• The company's third-party CMO may not meet deadlines or comply with regulations.
• The company may not be able to commercialize cosibelimab successfully.
• The company is dependent on third-party suppliers.
• The company needs substantial additional funds.
• There are risks related to the Russia/Ukraine conflict and COVID-19 pandemic.

Future Outlook

The company is focused on preparing for the potential approval of cosibelimab and is looking forward to potentially offering a new treatment option for patients with advanced cutaneous squamous cell carcinoma. They believe the $9.2 million in cash proceeds received this month from the exercise of existing warrants has strengthened their balance sheet to extend beyond their PDUFA date and into 2025.

Management Comments

• James Oliviero, President and Chief Executive Officer of Checkpoint, stated that they await the FDA's decision on the cosibelimab BLA resubmission.
• James Oliviero also mentioned that the recent cash proceeds have strengthened the balance sheet to extend beyond the PDUFA date and into 2025.

Industry Context

This announcement is relevant to the oncology and immunotherapy sectors, particularly companies developing treatments for solid tumor cancers. The progress of cosibelimab is being closely watched as it represents a potential new treatment option for advanced cutaneous squamous cell carcinoma. The collaboration with GC Cells Immuncell-LC also highlights the growing interest in combination therapies in oncology.

Comparison to Industry Standards

• Checkpoint Therapeutics is a clinical-stage company, so direct comparisons to revenue-generating pharmaceutical companies are not applicable.
• The company's R&D spending is typical for a company in its stage of development, focusing on clinical trials and regulatory submissions.
• The increase in G&A expenses is likely due to the company's preparations for potential commercialization of cosibelimab.
• The net loss is consistent with other clinical-stage biotech companies that are not yet generating revenue from product sales.
• Companies like Regeneron (REGN) and Merck (MRK) have approved anti-PD-1/PD-L1 therapies, and Checkpoint is aiming to differentiate cosibelimab with a dual mechanism of action and potentially favorable safety profile.
• The collaboration with GC Cells Immuncell-LC is similar to other companies exploring combination therapies, such as Bristol Myers Squibb (BMY) and their work with CAR T-cell therapies.

Stakeholder Impact

• Shareholders are impacted by the financial results and the progress of the cosibelimab BLA.
• Employees are impacted by the company's financial stability and future prospects.
• Patients with advanced cSCC may benefit from the potential approval of cosibelimab.
• Suppliers and creditors are impacted by the company's financial health.

Next Steps

• The company is awaiting the FDA's decision on the cosibelimab BLA resubmission, with a PDUFA goal date of December 28, 2024.
• Checkpoint is preparing for the potential approval and commercialization of cosibelimab.
• The company will continue to advance its other pipeline programs, including olafertinib.

Key Dates

Keywords

cosibelimab, checkpoint therapeutics, FDA, BLA, PDUFA, oncology, immunotherapy, cutaneous squamous cell carcinoma, cSCC, financial results, warrants, clinical trial, research and development, net loss